Kai Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai Ma has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Jie-Wen Zhang
Department of Neurology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
3 shared publications Rong Li
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou, 450003, China
2 shared publicationsShuai Chen
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
2 shared publicationsXiaodi Hao
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou, 450003, China
2 shared publicationsYu Shen
Department of Medical Imaging, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou, 450003, China
2 shared publications- Chao Han
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
1 shared publication
Latest Publications
- 27 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111683
Serum IGF-1 and anxiety trajectories in Parkinson's disease
- 27 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111683
Serum IGF-1 and anxiety trajectories in Parkinson's disease
- 24 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108294
Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction
- 24 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108294
Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction
- 18 February 2026
- Published by Elsevier in Autonomic Neuroscience
- Vol. 264, 103399
CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease
- 18 February 2026
- Published by Elsevier in Autonomic Neuroscience
- Vol. 264, 103399
CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease
- Open Access
- 25 November 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1170
Identification and validation of PANoptosis-related biomarkers in Alzheimer’s disease via single-cell RNA sequencing and machine learning
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with complex underlying mechanisms. PANoptosis, a newly defined form of programm
- 25 November 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1170
Open AccessIdentification and validation of PANoptosis-related biomarkers in Alzheimer’s disease via single-cell RNA sequencing and machine learning
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with complex underlying mechanisms. PANoptosis, a newly defined form of programm
- Open Access
- 16 April 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 670
Histone Deacetylase 4 Inhibition Reduces Rotenone-Induced Alpha-Synuclein Accumulation via Autophagy in SH-SY5Y Cells
(1) Background: Parkinson’s disease (PD) is the most common movement disorder. Imbalanced protein homeostasis and α-syn aggregation are involved in PD pathogenesis. Autophagy is related to the occurrence and development of PD and can be regulated by histone deacetylases (HDACs). Various inhibitors of HDACs exert neuroprotective effects within in vitro and in vivo models of PD. HDAC4, a class Ⅱ HDAC, colocalizes with α-synuclein and ubiquitin in Lewy bodies and also accumulates in the nuclei of dopaminergic neurons in PD models. (2) Methods: In the present study, the gene expression profile of HDACs from two previously reported datasets in the GEO database was analyzed, and the RNA levels of HDAC4 in brain tissues were compared between PD patients and healthy controls. In vitro, SH-SY5Y cells transfected with HDAC4 shRNA or pretreated with mc1568 were treated with 1 μM of rotenone for 24 h. Then, the levels of α-syn, LC3, and p62 were detected using Western blot analysis and immunofluorescent staining, and cell viabilities were detected using Cell Counting Kit-8 (CCK-8). (3) Results: HDAC4 was highly expressed in PD substantia nigra and locus coeruleus. Mc1568, an inhibitor of HDAC4, decreased α-synuclein levels in rotenone-treated SH-SY5Y cells in a concentration-dependent manner and activated autophagy, which was impaired by rotenone. The knockdown of HDAC4 reversed rotenone-induced α-syn accumulation in SH-SY5Y cells and protected the neurons by enhancing autophagy. (4) Conclusions: HDAC4 is a potential therapeutic target for PD. The inhibition of HDAC4 by mc1568 or a gene block can reduce α-syn levels by regulating the autophagy process in PD. Mc1568 is a promising therapeutic agent for PD and other disorders related to α-syn accumulation.
- 16 April 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 670
Open AccessHistone Deacetylase 4 Inhibition Reduces Rotenone-Induced Alpha-Synuclein Accumulation via Autophagy in SH-SY5Y Cells
(1) Background: Parkinson’s disease (PD) is the most common movement disorder. Imbalanced protein homeostasis and α-syn aggregation are involved in PD pathogenesis. Autophagy is related to the occurrence and development of PD and can be regulated by histone deacetylases (HDACs). Various inhibitors of HDACs exert neuroprotective effects within in vitro and in vivo models of PD. HDAC4, a class Ⅱ HDAC, colocalizes with α-synuclein and ubiquitin in Lewy bodies and also accumulates in the nuclei of dopaminergic neurons in PD models. (2) Methods: In the present study, the gene expression profile of HDACs from two previously reported datasets in the GEO database was analyzed, and the RNA levels of HDAC4 in brain tissues were compared between PD patients and healthy controls. In vitro, SH-SY5Y cells transfected with HDAC4 shRNA or pretreated with mc1568 were treated with 1 μM of rotenone for 24 h. Then, the levels of α-syn, LC3, and p62 were detected using Western blot analysis and immunofluorescent staining, and cell viabilities were detected using Cell Counting Kit-8 (CCK-8). (3) Results: HDAC4 was highly expressed in PD substantia nigra and locus coeruleus. Mc1568, an inhibitor of HDAC4, decreased α-synuclein levels in rotenone-treated SH-SY5Y cells in a concentration-dependent manner and activated autophagy, which was impaired by rotenone. The knockdown of HDAC4 reversed rotenone-induced α-syn accumulation in SH-SY5Y cells and protected the neurons by enhancing autophagy. (4) Conclusions: HDAC4 is a potential therapeutic target for PD. The inhibition of HDAC4 by mc1568 or a gene block can reduce α-syn levels by regulating the autophagy process in PD. Mc1568 is a promising therapeutic agent for PD and other disorders related to α-syn accumulation.
- 1 December 2015
- Published by Elsevier in Neuropharmacology
- Vol. 99, 448-458
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents
- 1 December 2015
- Published by Elsevier in Neuropharmacology
- Vol. 99, 448-458
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents